IMPACT OF ARTERIAL HYPERTENSION ON COVID-19
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.58043/rphrc.53 |
Resumo: | Introduction: SARS-CoV-2 binds to host cells through the angiotensin-converting enzyme 2. Several studies have suggested that hypertensive individuals, due to the overexpression of this enzyme in alveolar epithelial cells, may have a higher risk of contracting COVID-19 and having a more serious illness. In fact, arterial hypertension has been described as one of the most frequent comorbidities in patients with COVID-19 and has been suggested to be associated with a worse prognosis, namely higher mortality. However, many initial studies did not consider some confounding factors such as age, gender and the presence of other comorbidities, making their integration extremely important to better clarify the real impact of arterial hypertension on the development and course of COVID-19. Objectives: Investigate the prevalence of arterial hypertension in patients hospitalized due to COVID-19 and the classes of antihypertensive agents used by them. Analyze in COVID-19 patients the differences between the group of hypertensive and non-hypertensive patients regarding demographic characteristics, prevalence of frequent comorbidities, namely diabetes mellitus and heart failure, main symptoms of COVID-19, blood test and arterial blood gas results, radiographic evidence of pneumonia, bacterial superinfection, admission to intensive care unit, length of stay and mortality rate. Analyze the relationship between systolic and diastolic blood pressure at emergency department admission with demographic characteristics, comorbidities, main symptoms of COVID-19, radiographic evidence of pneumonia, initiation of antibiotic therapy for suspected bacterial superinfection, admission to an intensive care unit and mortality rate. Material and Methods: Retrospective study of patients hospitalized due COVID-19, at Centro Hospitalar Tondela-Viseu, from March 15 to May 18, 2020, using data from the clinical files of SClinico and ALERT® and statistics analysis through SPSS®. Results: Of the 89 patients hospitalized for COVID-19 during the study period, 38.20% were women. The mean age was 73.26 ± 16.26 years; 38.20% of patients were institutionalized. Of the total sample, 55.06% had arterial hypertension. When comparing hypertensive vs non-hypertensive patients, it was found that hypertensive patients were significantly older (mean age 80 vs 65 years, respectively, p=0.0002). The percentage of women was significantly higher in the hypertensive group when compared to the non-hypertensive group (51.02 vs 22.50%, p=0.006). The prevalence of diabetes mellitus was significantly higher in the hypertensive group (42.86 vs 12.50%, p=0.002), as well as heart failure (42.86 vs 15.00%, p=0.004). Of the main symptoms of COVID-19, dyspnea was more frequent in the hypertensive group (57.14 vs 52.50%, p=0.661), but not cough (42.90 vs 57.50%, p=0.169), nor fever (44.90 vs 55.00%, p=0.343). There were no significant differences between groups regarding blood test and arterial blood gas results at emergency department admission, namely: leukocytes (10.5 vs 9.23 x 109/L, p=0.361), neutrophils (7.39 vs 7.09 x 109/L, p=0.801), lymphocytes (1.20 vs. 1.18 x 109/L, p=0.801), platelets (213.64 vs 207.15 x 109/L, p=0.723), C-reactive protein (7.99 vs 7.74 mg/dL, p=0.862), procalcitonin (1.82 vs 4.08 ng/ml, p=0.516), arterial pH (7.45 vs 7.44, p=0.715), lactates (1.77 vs 1.33 mmol/L, p=0.294) and the PaO2/FiO2 ratio (254.60 vs 278.26, p=0.211). The percentage of patients with radiographic evidence of pneumonia was identical in both groups (55.10 vs 65.00%, p=0.344), as well the start of antibiotic therapy for suspected bacterial superinfection (67.35 vs 62.50%, p=0.633). There were no significant differences in the need for admission to an intensive care unit (8.16 vs 15.00%, p=0.335). The average length of stay in the hospital was slightly higher in the hypertensive group (19.08 vs 14.95 days, p=0.173), but there were no significant differences in mortality (12.24 vs 17.50%, p=0.485). Conclusions: As described in the literature, arterial hypertension was highly prevalent in our sample and these patients were, on average, older and had more comorbidities. Even so, no significant differences were found in the clinical presentation, blood tests and radiographic changes, nor in the disease severity and prognosis. |
id |
RCAP_9138ae5fc88a1f87992e4b858dbbe272 |
---|---|
oai_identifier_str |
oai:ojs.revistahipertensao.pt:article/53 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
IMPACT OF ARTERIAL HYPERTENSION ON COVID-19IMPACTO DA HIPERTENSÃO ARTERIAL NA COVID-19Hipertensão arterialpressão arterial sistólicapressão arterial diastólicaCOVID-19SARS-CoV-2pneumoniaArterial hypertensionsystolic blood pressurediastolic blood pressureCOVID-19SARS-CoV-2pneumoniaIntroduction: SARS-CoV-2 binds to host cells through the angiotensin-converting enzyme 2. Several studies have suggested that hypertensive individuals, due to the overexpression of this enzyme in alveolar epithelial cells, may have a higher risk of contracting COVID-19 and having a more serious illness. In fact, arterial hypertension has been described as one of the most frequent comorbidities in patients with COVID-19 and has been suggested to be associated with a worse prognosis, namely higher mortality. However, many initial studies did not consider some confounding factors such as age, gender and the presence of other comorbidities, making their integration extremely important to better clarify the real impact of arterial hypertension on the development and course of COVID-19. Objectives: Investigate the prevalence of arterial hypertension in patients hospitalized due to COVID-19 and the classes of antihypertensive agents used by them. Analyze in COVID-19 patients the differences between the group of hypertensive and non-hypertensive patients regarding demographic characteristics, prevalence of frequent comorbidities, namely diabetes mellitus and heart failure, main symptoms of COVID-19, blood test and arterial blood gas results, radiographic evidence of pneumonia, bacterial superinfection, admission to intensive care unit, length of stay and mortality rate. Analyze the relationship between systolic and diastolic blood pressure at emergency department admission with demographic characteristics, comorbidities, main symptoms of COVID-19, radiographic evidence of pneumonia, initiation of antibiotic therapy for suspected bacterial superinfection, admission to an intensive care unit and mortality rate. Material and Methods: Retrospective study of patients hospitalized due COVID-19, at Centro Hospitalar Tondela-Viseu, from March 15 to May 18, 2020, using data from the clinical files of SClinico and ALERT® and statistics analysis through SPSS®. Results: Of the 89 patients hospitalized for COVID-19 during the study period, 38.20% were women. The mean age was 73.26 ± 16.26 years; 38.20% of patients were institutionalized. Of the total sample, 55.06% had arterial hypertension. When comparing hypertensive vs non-hypertensive patients, it was found that hypertensive patients were significantly older (mean age 80 vs 65 years, respectively, p=0.0002). The percentage of women was significantly higher in the hypertensive group when compared to the non-hypertensive group (51.02 vs 22.50%, p=0.006). The prevalence of diabetes mellitus was significantly higher in the hypertensive group (42.86 vs 12.50%, p=0.002), as well as heart failure (42.86 vs 15.00%, p=0.004). Of the main symptoms of COVID-19, dyspnea was more frequent in the hypertensive group (57.14 vs 52.50%, p=0.661), but not cough (42.90 vs 57.50%, p=0.169), nor fever (44.90 vs 55.00%, p=0.343). There were no significant differences between groups regarding blood test and arterial blood gas results at emergency department admission, namely: leukocytes (10.5 vs 9.23 x 109/L, p=0.361), neutrophils (7.39 vs 7.09 x 109/L, p=0.801), lymphocytes (1.20 vs. 1.18 x 109/L, p=0.801), platelets (213.64 vs 207.15 x 109/L, p=0.723), C-reactive protein (7.99 vs 7.74 mg/dL, p=0.862), procalcitonin (1.82 vs 4.08 ng/ml, p=0.516), arterial pH (7.45 vs 7.44, p=0.715), lactates (1.77 vs 1.33 mmol/L, p=0.294) and the PaO2/FiO2 ratio (254.60 vs 278.26, p=0.211). The percentage of patients with radiographic evidence of pneumonia was identical in both groups (55.10 vs 65.00%, p=0.344), as well the start of antibiotic therapy for suspected bacterial superinfection (67.35 vs 62.50%, p=0.633). There were no significant differences in the need for admission to an intensive care unit (8.16 vs 15.00%, p=0.335). The average length of stay in the hospital was slightly higher in the hypertensive group (19.08 vs 14.95 days, p=0.173), but there were no significant differences in mortality (12.24 vs 17.50%, p=0.485). Conclusions: As described in the literature, arterial hypertension was highly prevalent in our sample and these patients were, on average, older and had more comorbidities. Even so, no significant differences were found in the clinical presentation, blood tests and radiographic changes, nor in the disease severity and prognosis.Introdução: O SARS-CoV-2 liga-se às células do hospedeiro através da enzima conversora da angiotensina 2. Vários estudos sugeriram que os hipertensos, pela expressão aumentada desta enzima nas células epiteliais alveolares, poderiam ter mais risco de contrair COVID-19 e ter um curso de doença mais grave. De facto, a hipertensão arterial foi descrita como uma das comorbilidades mais frequentes nos doentes com COVID-19 e foi sugerido associar-se a um pior prognóstico, nomeadamente a uma maior mortalidade. Contudo, muitos estudos iniciais não tiveram em conta alguns fatores confundidores como a idade, género e presença de outras comorbilidades, tornando-se de extrema importância a sua integração para melhor esclarecer o real impacto da hipertensão arterial no desenvolvimento e curso da COVID-19. Objetivos: Averiguar a prevalência da hipertensão arterial em doentes internados por COVID-19 e as classes de anti-hipertensores por eles realizados. Analisar em doentes com COVID-19 as diferenças entre o grupo de doentes hipertensos e não hipertensos quanto a características demográficas, prevalência de comorbilidades frequentes, nomeadamente de diabetes mellitus e insuficiência cardíaca, sintomas mais frequentes de COVID-19, parâmetros analíticos e gasométricos, evidência radiográfica de pneumonia, sobreinfeção bacteriana, necessidade de internamento em unidade de cuidados intensivos, duração do internamento e taxa de mortalidade. Analisar a relação entre o valor de pressão arterial sistólica e diastólica na admissão no serviço de urgência com as características demográficas, comorbilidades, sintomas mais frequentes de infeção por SARS-CoV-2, evidência radiográfica de pneumonia, início de antibioterapia por suspeita de sobreinfeção bacteriana, necessidade de internamento em unidade cuidados intensivos e taxa de mortalidade. Material e Métodos: Estudo retrospetivo dos doentes internados por COVID-19, no Centro Hospitalar Tondela-Viseu, de 15 de Março a 18 de Maio de 2020, com recurso aos dados dos processos clínicos do SClínico e ALERT® e análise estatística através do SPSS®. Resultados: Dos 89 doentes internados por COVID-19 no período em estudo, 38.20% eram mulheres. A idade média foi de 73.26 ± 16.26 anos. Estavam institucionalizados 38.20% dos doentes. Do total da amostra, 55.06% eram hipertensos. Quando comparado os grupos de doentes hipertensos vs os não hipertensos, verificou-se que os hipertensos eram significativamente mais velhos (média de idades de 80 vs 65 anos, respetivamente, p=0.0002). A percentagem de mulheres foi significativamente superior no grupo dos hipertensos quando comparada com os não hipertensos (51.02 vs 22.50%, p=0.006). A prevalência de diabetes mellitus foi significativamente superior no grupo dos hipertensos (42.86 vs 12.50%, p=0.002), assim como a insuficiência cardíaca (42.86 vs 15.00%, p=0.004). Dos sintomas mais prevalentes da COVID-19, a dispneia foi mais frequente no grupo dos hipertensos (57.14 vs 52.50%, p=0.661), mas não a tosse (42.90 vs 57.50%, p=0.169), nem a febre (44.90 vs 55.00%, p=0.343). Não se verificaram diferenças significativas entre grupos quanto aos parâmetros analíticos e gasométricos no serviço de urgência, nomeadamente: leucócitos (10.5 vs 9.23 x 109/L, p=0.361), neutrófilos (7.39 vs 7.09 x 109/L, p=0.801), linfócitos (1.20 vs 1.18 x 109/L, p=0.801), plaquetas (213.64 vs 207.15 x 109/L, p=0.723), proteína C reativa (7.99 vs 7.74 mg/dL, p=0.862), procalcitonina (1.82 vs 4.08 ng/mL, p=0.516), pH do sangue arterial (7.45 vs 7.44, p=0.715), lactatos (1.77 vs 1.33 mmol/L, p=0.294) e a razão PaO2/FiO2 (254.60 vs 278.26, p=0.211). A percentagem de doentes com evidência radiográfica de pneumonia foi idêntica nos dois grupos (55.10 vs 65.00%, p=0.344), assim como o início de antibioterapia por suspeita de sobreinfeção bacteriana (67.35 vs 62.50%, p=0.633). Não se verificaram diferenças significativas na necessidade de internamento em unidade de cuidados intensivos (8.16 vs 15.00%, p=0.335). O número médio de dias de internamento foi ligeiramente superior no grupo dos hipertensos (19.08 vs 14.95 dias, p=0.173), mas não houve diferenças significativas na mortalidade (12.24 vs 17.50%, p=0.485). Conclusões: À semelhança do descrito na literatura, a HTA foi altamente prevalente na nossa amostra e estes doentes eram em média mais velhos e tinham mais comorbilidades. Ainda assim, não foram verificadas diferenças significativas na apresentação clínica, alterações analíticas e radiográficas, nem na gravidade da doença e no seu prognóstico.Revista Portuguesa de Hipertensão e Risco Cardiovascular2023-02-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.58043/rphrc.53https://doi.org/10.58043/rphrc.53Revista Portuguesa de Hipertensão e Risco Cardiovascular; N.º 93 (2023): Janeiro/Fevereiro; 10-181646-8287reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revistahipertensao.pt/index.php/rh/article/view/53https://revistahipertensao.pt/index.php/rh/article/view/53/56Direitos de Autor (c) 2023 Inês Cunha, Daniel Aparício, Andreia Lopes, Inês Bagnari, Joana Cunha, Rui Marques, Vera Romãoinfo:eu-repo/semantics/openAccessCunha, InêsAparício, DanielLopes, AndreiaBagnari, InêsCunha, JoanaMarques, RuiRomão, Vera2024-02-03T07:36:46Zoai:ojs.revistahipertensao.pt:article/53Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:46:08.706772Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
IMPACT OF ARTERIAL HYPERTENSION ON COVID-19 IMPACTO DA HIPERTENSÃO ARTERIAL NA COVID-19 |
title |
IMPACT OF ARTERIAL HYPERTENSION ON COVID-19 |
spellingShingle |
IMPACT OF ARTERIAL HYPERTENSION ON COVID-19 Cunha, Inês Hipertensão arterial pressão arterial sistólica pressão arterial diastólica COVID-19 SARS-CoV-2 pneumonia Arterial hypertension systolic blood pressure diastolic blood pressure COVID-19 SARS-CoV-2 pneumonia |
title_short |
IMPACT OF ARTERIAL HYPERTENSION ON COVID-19 |
title_full |
IMPACT OF ARTERIAL HYPERTENSION ON COVID-19 |
title_fullStr |
IMPACT OF ARTERIAL HYPERTENSION ON COVID-19 |
title_full_unstemmed |
IMPACT OF ARTERIAL HYPERTENSION ON COVID-19 |
title_sort |
IMPACT OF ARTERIAL HYPERTENSION ON COVID-19 |
author |
Cunha, Inês |
author_facet |
Cunha, Inês Aparício, Daniel Lopes, Andreia Bagnari, Inês Cunha, Joana Marques, Rui Romão, Vera |
author_role |
author |
author2 |
Aparício, Daniel Lopes, Andreia Bagnari, Inês Cunha, Joana Marques, Rui Romão, Vera |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Cunha, Inês Aparício, Daniel Lopes, Andreia Bagnari, Inês Cunha, Joana Marques, Rui Romão, Vera |
dc.subject.por.fl_str_mv |
Hipertensão arterial pressão arterial sistólica pressão arterial diastólica COVID-19 SARS-CoV-2 pneumonia Arterial hypertension systolic blood pressure diastolic blood pressure COVID-19 SARS-CoV-2 pneumonia |
topic |
Hipertensão arterial pressão arterial sistólica pressão arterial diastólica COVID-19 SARS-CoV-2 pneumonia Arterial hypertension systolic blood pressure diastolic blood pressure COVID-19 SARS-CoV-2 pneumonia |
description |
Introduction: SARS-CoV-2 binds to host cells through the angiotensin-converting enzyme 2. Several studies have suggested that hypertensive individuals, due to the overexpression of this enzyme in alveolar epithelial cells, may have a higher risk of contracting COVID-19 and having a more serious illness. In fact, arterial hypertension has been described as one of the most frequent comorbidities in patients with COVID-19 and has been suggested to be associated with a worse prognosis, namely higher mortality. However, many initial studies did not consider some confounding factors such as age, gender and the presence of other comorbidities, making their integration extremely important to better clarify the real impact of arterial hypertension on the development and course of COVID-19. Objectives: Investigate the prevalence of arterial hypertension in patients hospitalized due to COVID-19 and the classes of antihypertensive agents used by them. Analyze in COVID-19 patients the differences between the group of hypertensive and non-hypertensive patients regarding demographic characteristics, prevalence of frequent comorbidities, namely diabetes mellitus and heart failure, main symptoms of COVID-19, blood test and arterial blood gas results, radiographic evidence of pneumonia, bacterial superinfection, admission to intensive care unit, length of stay and mortality rate. Analyze the relationship between systolic and diastolic blood pressure at emergency department admission with demographic characteristics, comorbidities, main symptoms of COVID-19, radiographic evidence of pneumonia, initiation of antibiotic therapy for suspected bacterial superinfection, admission to an intensive care unit and mortality rate. Material and Methods: Retrospective study of patients hospitalized due COVID-19, at Centro Hospitalar Tondela-Viseu, from March 15 to May 18, 2020, using data from the clinical files of SClinico and ALERT® and statistics analysis through SPSS®. Results: Of the 89 patients hospitalized for COVID-19 during the study period, 38.20% were women. The mean age was 73.26 ± 16.26 years; 38.20% of patients were institutionalized. Of the total sample, 55.06% had arterial hypertension. When comparing hypertensive vs non-hypertensive patients, it was found that hypertensive patients were significantly older (mean age 80 vs 65 years, respectively, p=0.0002). The percentage of women was significantly higher in the hypertensive group when compared to the non-hypertensive group (51.02 vs 22.50%, p=0.006). The prevalence of diabetes mellitus was significantly higher in the hypertensive group (42.86 vs 12.50%, p=0.002), as well as heart failure (42.86 vs 15.00%, p=0.004). Of the main symptoms of COVID-19, dyspnea was more frequent in the hypertensive group (57.14 vs 52.50%, p=0.661), but not cough (42.90 vs 57.50%, p=0.169), nor fever (44.90 vs 55.00%, p=0.343). There were no significant differences between groups regarding blood test and arterial blood gas results at emergency department admission, namely: leukocytes (10.5 vs 9.23 x 109/L, p=0.361), neutrophils (7.39 vs 7.09 x 109/L, p=0.801), lymphocytes (1.20 vs. 1.18 x 109/L, p=0.801), platelets (213.64 vs 207.15 x 109/L, p=0.723), C-reactive protein (7.99 vs 7.74 mg/dL, p=0.862), procalcitonin (1.82 vs 4.08 ng/ml, p=0.516), arterial pH (7.45 vs 7.44, p=0.715), lactates (1.77 vs 1.33 mmol/L, p=0.294) and the PaO2/FiO2 ratio (254.60 vs 278.26, p=0.211). The percentage of patients with radiographic evidence of pneumonia was identical in both groups (55.10 vs 65.00%, p=0.344), as well the start of antibiotic therapy for suspected bacterial superinfection (67.35 vs 62.50%, p=0.633). There were no significant differences in the need for admission to an intensive care unit (8.16 vs 15.00%, p=0.335). The average length of stay in the hospital was slightly higher in the hypertensive group (19.08 vs 14.95 days, p=0.173), but there were no significant differences in mortality (12.24 vs 17.50%, p=0.485). Conclusions: As described in the literature, arterial hypertension was highly prevalent in our sample and these patients were, on average, older and had more comorbidities. Even so, no significant differences were found in the clinical presentation, blood tests and radiographic changes, nor in the disease severity and prognosis. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-02-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.58043/rphrc.53 https://doi.org/10.58043/rphrc.53 |
url |
https://doi.org/10.58043/rphrc.53 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://revistahipertensao.pt/index.php/rh/article/view/53 https://revistahipertensao.pt/index.php/rh/article/view/53/56 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Revista Portuguesa de Hipertensão e Risco Cardiovascular |
publisher.none.fl_str_mv |
Revista Portuguesa de Hipertensão e Risco Cardiovascular |
dc.source.none.fl_str_mv |
Revista Portuguesa de Hipertensão e Risco Cardiovascular; N.º 93 (2023): Janeiro/Fevereiro; 10-18 1646-8287 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130932674822144 |